Thousands of people in Texas have been displaced from their homes after Hurricane Harvey landed there last week, leaving many without life-saving medication and supplies. People with diabetes are especially vulnerable, since many require daily insulin injections and regular monitoring of their blood glucose levels. In what they have described as a ‘landmark partnership’, the […]
Juvenile Diabetes Research Foundation (JDRF)
IBM partners to identify risk factors for Type I diabetes
IBM (NYSE:IBM) plans to develop and apply machine learning techniques to years of research data in the hopes of identifying factors that trigger the onset of Type I diabetes in children, with the support of JDRF. Scientists at IBM are slated to assess three different data sets using machine learning algorithms to find patterns and factors that could […]
ViaCyte launches cell replacement trial for Type I diabetes
Regenerative medicine company ViaCyte said today that the first patients have been implanted in a trial of its islet cell replacement therapy, PEC-Direct. San Diego-based ViaCyte is developing the cell therapy as a functional cure for patients with Type I diabetes who are at risk of suffering acute life-threatening complications. Get the full story at our sister […]
Provention Bio wants to stop Type I diabetes – with a vaccine
Before he co-founded Provention Bio, Ashleigh Palmer worked on inhaled nitric oxide for infants with respiratory failure. After the company was sold for $1.2 billion to a Baxter-led consortium, Palmer noticed there was apprehension about conducting clinical trials with neonates. He was concerned that the inhaled NO assets were slated to fall to the wayside. […]
Provention Bio evaluates vaccine to prevent onset of T1D
Provention Bio said today that it licensed an enterovirus vaccine platform that it plans to evaluate as a way to prevent the onset of Type I diabetes by vaccinating against infection by a coxsackievirus B pathogen. Previous work has shown that CVB infection could be responsible for 50% of Type I diabetes cases worldwide, according to […]
Hydrogel tech boosts success of transplanted insulin-producing cells
A hydrogel material embedded with a protein to improve blood vessel growth may boost the success rate of transplanting insulin-producing islet cells into patients with Type I diabetes, according to a preclinical study published in the journal Science Advances. In the newly-published work, supported by the National Institutes of Health and the Juvenile Diabetes Research Foundation, […]
ViaCyte looks to cell replacement therapy to cure Type I diabetes
ViaCyte said today that it will begin clinical trials of its novel islet cell replacement therapy in development as a potential cure for Type I diabetes, after landing regulatory wins from the FDA and Health Canada. The company’s PEC-Direct candidate delivers stem cell-derived pancreatic progenitor cells in a device that is designed to enable direct […]
Canadian government, JDRF ink $30m partnership to support diabetes research
Canada’s Minister of Health, Jane Philpott, said today that the Canadian Institutes of Health Research inked a $30 million partnership with the Juvenile Diabetes Research Foundation to support clinical research for Type I diabetes. Both groups have agreed to invest $15 million to the deal. “The government of Canada recognizes the impact that Type I diabetes […]
JDRF backs Bigfoot Biomedical with equity investment
The Juvenile Diabetes Research Foundation said today that its T1D Fund made an unspecified equity investment in Bigfoot Biomedical and the Smartloop automated insulin delivery system it’s developing. “We are thrilled to have a fund associated with the world’s largest nonprofit funder of [Type I diabetes] research as an investor,” Bigfoot president & CEO Jeffrey Brewer […]
BD, JDRF ink deal for extended wear insulin delivery device
Becton Dickinson (NYSE:BDX) said today that it inked a research collaboration supported by the Juvenile Diabetes Research Foundation to develop an extended-wear insulin delivery device. The collaboration is a 2-year funding commitment from JDRF to extend the lifetime of insulin infusion-delivery devices. Insulin infusion sets are cleared by the FDA for up to 3 days of […]
Sernova, CTI ink regulatory deal for Cell Pouch System
Sernova said it inked a regulatory deal with CTI Clinical Trial and Consulting Services to further the clinical development and IND application for its Cell Pouch drug delivery system. The London, Ontario-based company’s Cell Pouch is an implantable device that acts as an environment within the body to store therapeutic cells for patients with chronic diseases. Get […]